March 3, 2011
Research Into Chromosome Replication Reveals Details Of Heredity Dynamics
A novel study from Karolinska Institutet has deepened the understanding of how chromosome replication, one of life's most fundamental processes, works. In a long term perspective these results could eventually lead to novel cancer therapies. The study is presented in the prestigious scientific journal Nature.
By studying DNA replication in yeast cells, researchers at Karolinska Institutet have discovered that a protein complex (Smc5/6) helps to release torsional stress created in the DNA molecule when chromosomes are replicated in preparation for a coming cell division.
The study therefore sheds more light on the mechanisms behind one of life's most fundamental processes. Since topoisomerases, enzymes known to remove replication-related stress in the DNA are common targets for cancer treatments, the finding might eventually lead to new therapies.
When a fertilised egg develops into a complete organism, or when old cells are replaced by new ones, it is done through cell division. If human daughter cells are to survive and develop normally, they must each obtain a full set of 46 chromosomes, which are made of double-stranded DNA helices. Since the original mother cell started as a cell with 46 chromosomes, these must be duplicated before division take place.
During this process, the DNA double helix is separated so that the replication machinery can reach the individual DNA strands. This prising apart of the strands creates stress in the form of over-twisted DNA in the vicinity of the replication zone. If this stress is not removed, replication can be slowed down or even stopped, and this, in turn, can lead to mutagenesis and/or cell death.
"Several modern cancer treatments attack topoisomerases, but there's a problem in that some cancers become resistant to such therapies," says Professor Sjögren. "Now that we've discovered that also the Smc5/6 complex releases the stress which form during the replication process, our results might trigger the development of drugs that target Smc5/6. This could create another tool for inhibiting tumour growth."
Camilla Sjögren is a Royal Swedish Academy of Sciences Research Fellow supported by the Knut and Alice Wallenberg Foundation. This work was also financed the European Research Council (ERC-starting grant), the Swedish Research Council (VR), the Swedish Cancer Society, Vinnova, the Swedish foundation for Strategic research (SSF), Japan Science and Technology Agency, the Ministry of Education, Culture, Sports, Science and Technology, the Japan Society for the Promotion of Science, and Cornell's and Karolinska Institutet's research foundations.
On the Net: